<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159587</url>
  </required_header>
  <id_info>
    <org_study_id>11856</org_study_id>
    <nct_id>NCT01159587</nct_id>
  </id_info>
  <brief_title>Prophylaxis Versus On-demand Therapy Through Economic Report</brief_title>
  <acronym>POTTER</acronym>
  <official_title>Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A. POTTER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project is a controlled observational, multicenter, prospective data collection on
      secondary prophylaxis with Kogenate Bayer in adolescents and adults with severe haemophilia A
      (FVIII &lt; 1%).

      The observational period will cover at least 5 years per patient.

      The long-term secondary prophylaxis group will be compared versus on-demand treatment group
      by the assessment of orthopedic status progression and pharmacoeconomics evaluation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy, safety and pharmacoeconomic of long-term secondary prophylaxis with Kogenate Bayer in comparison to on-demand treatment with Kogenate Bayer in terms of joint bleeding episodes per year</measure>
    <time_frame>Every 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy, safety, pharmacoeconomic impact of secondary prophylaxis versus on demand group in terms of overall bleeding episodes</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscolo skeletal evaluation by Orthopedic Joint Score</measure>
    <time_frame>Every 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological Evaluation by Pettersson Score</measure>
    <time_frame>Baseline and after 3-5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>Every 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost-effectiveness and utility, patient compliance, adverse events</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">58</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Factor VIII (Kogenate FS, BAY14-2222)</intervention_name>
    <description>Long-term secondary prophylaxis with product administered 20-30 UI /kg three times weekly</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Factor VIII (Kogenate FS, BAY14-2222)</intervention_name>
    <description>On-demand treatment with product given only for bleeding episodes</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Haemophilics
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥ 12 years and ≤ 55 years

          -  severe haemophilia A (FVIII &lt; 1%)

          -  absence of inhibitors (Bethesda titre &lt; 0.6 BU/ml)

          -  Previous Treated Patients (prior exposure days &gt; 200)

          -  Kogenate Bayer administered 20-30 IU/kg -3 times a week, for the prophylaxis group

          -  ≥ 6 joint bleeds requiring treatment with FVIII concentrates in the previous 6 months
             before enrollment, for on-demand group

          -  written informed consent

        Exclusion Criteria:

          -  concomitant severe and chronic diseases or congenital skeletal malformation

          -  unreliability of patient or likelihood of follow-up failure

          -  presence of inhibitors or history of inhibitors (in the previous 2 years)

          -  currently on immune tolerance treatment

          -  hepatic cirrhosis or liver disease in rapid progression

          -  AIDS

          -  platelet count &lt; 75,000/mm3

          -  presence of conditions that influence negatively patient´s compliance

          -  participation in another study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2010</study_first_posted>
  <last_update_submitted>April 12, 2011</last_update_submitted>
  <last_update_submitted_qc>April 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Bayser Schering Pharma AG</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

